Akebia Therapeutics Provides Update on Vadadustat Development Program
Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease
Akebia’s vadadustat successful in mid-stage study in Japan, Phase 3 planned; shares ahead 5% premarket
